SCHEMBL4020512

SCHEMBL4020512

CN(C)C(=O)c1cc(N)ccc1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.64
HPGD P15428 4/20 0.46
HTT P42858 1/20 0.46
CYP3A4 P08684 4/20 0.43
TSHR P16473 2/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 2/20 0.41
MTOR P42345 2/20 0.40
P2RX7 Q99572 1/20 0.40
THRB P10828 3/20 0.40
RECQL P46063 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
ALOX15 P16050 2/20 0.40
CASP1 P29466 2/20 0.40
HSD17B10 Q99714 2/20 0.40
POLB P06746 2/20 0.40
APEX1 P27695 2/20 0.40
USP2 O75604 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3174627 0.85 ALDH1A1 (0.50) ALDH1A1HPGDHTTCYP3A4TSHR
SCHEMBL1043126 0.81 ALDH1A1 (0.68) ALDH1A1HPGDHTTTSHRMEN1
SCHEMBL1708822 0.81 KMT2A (0.57) ALDH1A1HPGDCYP3A4MEN1KMT2A
SCHEMBL15597493 0.81 ALDH1A1 (0.42) ALDH1A1HPGDCYP3A4TSHRMEN1
SCHEMBL16942492 0.81 HSP90AA1 (0.47) ALDH1A1HPGDCYP3A4TSHRMAPT
SCHEMBL3784574 0.79 ALDH1A1 (0.66) ALDH1A1HPGDHTTTSHRMEN1
SCHEMBL17774838 0.79 KDM4E (0.60) ALDH1A1HPGDCYP3A4TSHRMEN1
SCHEMBL509010 0.79 CASP1 (0.45) ALDH1A1HPGDCYP3A4TSHRMEN1
SCHEMBL4363897 0.79 ALDH1A1 (0.66) ALDH1A1HPGDHTTMEN1KMT2A
SCHEMBL1099858 0.79 CYP3A4 (0.48) ALDH1A1HPGDCYP3A4TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014028931-A2 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS BRANDEIS UNIVERSITY (US) 2014-02-20 WO disclosed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 US disclosed
WO-2009089042-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 ALDH1A1 4322/4885HPGD 1834/4885HTT 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.